Stockscreener 앱 받기
33.26
0.70%
0.23
Viridian Therapeutics Inc 주식(VRDN)의 최신 뉴스
Viridian Therapeutics stock hits 52-week high at $34.06 By Investing.com - Investing.com Nigeria
Responsive Playbooks and the VRDN Inflection - Stock Traders Daily
Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline - TechStock²
Viridian Therapeutics (NASDAQ:VRDN) Reaches New 52-Week HighStill a Buy? - MarketBeat
Viridian Therapeutics stock hits 52-week high at $34.06 - Investing.com
Market Review: Is Viridian Therapeutics Inc stock a good pick for beginnersPortfolio Return Report & Capital Efficiency Focused Ideas - baoquankhu1.vn
Viridian Therapeutics, Inc. (VRDN): Growth Potential in Biotechnology with an 81,958% Revenue Surge - DirectorsTalk Interviews
Will Viridian Therapeutics Inc. stock continue upward momentumJuly 2025 Decliners & Real-Time Buy Zone Alerts - Улправда
Viridian Therapeutics (NASDAQ:VRDN) Upgraded by UBS Group to "Strong-Buy" Rating - MarketBeat
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 8, 2026 - BioSpace
Assessing Viridian Therapeutics (VRDN) Valuation After FDA Priority Review For Veligrotug - Sahm
What MACD trends signal for Viridian Therapeutics Inc. (1S1) stockPortfolio Performance Report & Expert Curated Trade Setup Alerts - ulpravda.ru
Will Viridian Therapeutics Inc. stock continue dividend increasesJuly 2025 Short Interest & Low Drawdown Trading Techniques - ulpravda.ru
Is Viridian Therapeutics Inc. stock attractive after correctionCPI Data & Technical Entry and Exit Alerts - Улправда
How Viridian Therapeutics Inc. stock compares to market leaders2025 Trading Volume Trends & Expert Approved Momentum Ideas - Улправда
Viridian Therapeutics, Inc.Common Stock (NQ: VRDN - FinancialContent
Why CHRO stock attracts strong analyst attention - Улправда
Can Viridian Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Market Review & Real-Time Chart Pattern Alerts - Улправда
VRDN: Truist Securities Lowers Price Target but Maintains Buy Ra - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $40.00 at Truist Financial - MarketBeat
Why Viridian Therapeutics Inc. stock is in analyst buy zonePortfolio Gains Report & Smart Investment Allocation Insights - Улправда
Oklahoma City NewsThe Oklahoman - FinancialContent
UBS Initiates Coverage of Viridian Therapeutics (VRDN) with Buy Recommendation - Nasdaq
Will Viridian Therapeutics Inc. stock deliver consistent dividendsLong-Term Growth Stocks & Turn Market Volatility into Wealth - Улправда
VRDN: UBS Initiates Coverage with a 'Buy' Rating and $50 Price T - GuruFocus
Why Viridian Therapeutics Inc. stock remains resilientHigh Beta Stocks & Outstanding Portfolio Tips - Улправда
Free cash flow per share of Viridian Therapeutics, Inc. – DUS:1S1 - TradingView — Track All Markets
UBS initiates Viridian Therapeutic stock with Buy rating on TED treatment - Investing.com Canada
Jefferies reiterates Buy rating on Viridian Therapeutic stock with $44 target - Investing.com Canada
Viridian Therapeutic stock a Top Pick at TD Cowen ahead of busy 2026 - Investing.com Canada
Viridian Therapeutics Prepares for Transformational 2026 - BioSpace
Viridian Therapeutics, Inc. (VRDN) Investor Outlook: Exploring a Potential 36.59% Upside in the Biotech Arena - DirectorsTalk Interviews
About Us | Laser Focus WorldViridian Therapeutics Prepares for Transformational 2026 - FinancialContent
Entry Recap: Will Viridian Therapeutics Inc. stock outperform international peersMarket Volume Report & Consistent Profit Trading Strategies - ulpravda.ru
Is Viridian Therapeutics Inc. stock positioned for long term growth2026 world cup usa national team qualification midfield engines high defensive line tactical prediction insights - ulpravda.ru
Viridian Therapeutics’ Veligrotug Shows Durable Proptosis Response in Phase 3 TED Trial - MSN
VRDN Stock Price, Forecast & Analysis | VIRIDIAN THERAPEUTICS INC (NASDAQ:VRDN) - Chartmill
Understanding the Setup: (VRDN) and Scalable Risk - Stock Traders Daily
Viridian Therapeutics Earnings Notes - Trefis
Viridian Therapeutics (NASDAQ:VRDN) Insider Sells $70,795.52 in Stock - MarketBeat
Insider Sell: Jennifer Tousignant Sells 2,272 Shares of Viridian Therapeutics Inc (VRDN) - GuruFocus
Viridian Therapeutics (VRDN) Chief Legal Officer reports 2,272-share stock sale - Stock Titan
What to keep an eye on in 2026 - Eyes On Eyecare
What analysts say about Viridian Therapeutics Inc stockGrowth vs. Value Investing & Low Risk Investment Tips - earlytimes.in
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Benzinga
Simplify Asset Management Inc. Purchases Shares of 50,000 Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Market Fear: How Viridian Therapeutics Inc 1S1 stock performs during market turbulenceJuly 2025 Sector Moves & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
Rice Hall James & Associates LLC Purchases 336,040 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), MDxHealth (MDXH) and RxSight (RXST) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (VRDN), Fortrea Holdings Inc. (FTRE) and Cytokinetics (CYTK) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Sanofi (OtherSNYNF) - The Globe and Mail
VRDN: Needham Maintains Buy Rating and Raises Price Target | VRD - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $42.00 at Needham & Company LLC - MarketBeat
Viridian Therapeutics, Inc. (VRDN) Stock Analysis: Unlocking a 27% Potential Upside in Biotech - DirectorsTalk Interviews
Viridian Therapeutics: De-Risked Veligrotug Program and Compelling Phase III Data Support Undervalued Buy Rating - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Viridian Therapeutics (VRDN) - The Globe and Mail
Viridian Therapeutics Says FDA Accepts Biologics License Application for Veligrotug - marketscreener.com
Viridian Therapeutics (VRDN) Gains FDA Priority Review for Thyro - GuruFocus
FDA grants priority review for Viridian’s thyroid eye disease drug - Investing.com
Viridian Therapeutics announces BLA acceptance and Priority Review for Veligrotug for the treatment of thyroid eye disease - marketscreener.com
Viridian Therapeutics Announces BLA Acceptance And Priority Review For Veligrotug For The Treatment Of Thyroid Eye Disease - TradingView — Track All Markets
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease - Business Wire
4.73%
0.92%
자본화:
|
볼륨(24시간):